MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

Consensus Ratings for Bellicum Pharmaceuticals (NASDAQ:BLCM) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $28.00 (125.44% upside)

Analysts' Ratings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016SunTrustInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Piper JaffrayReiterated RatingBuy$45.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Jefferies GroupLower Price TargetBuy$35.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015GuggenheimUpgradeNeutral -> Buy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016($0.51)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.22)($0.30)$0.11 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q4($11.79)($18.99)$0.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.50)($0.50)($0.50)
Q2 20162($0.60)($0.59)($0.60)
Q3 20162($0.64)($0.60)($0.62)
Q4 20162($0.62)($0.57)($0.60)
(Data provided by Zacks Investment Research)
Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Bellicum Pharmaceuticals (NASDAQ:BLCM)
DateHeadline
06/24/16 08:00 PMShare Volatility Check for: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Press Telegraph
06/23/16 10:18 PMCould Bellicum Pharmaceuticals Inc See a Reversal After This Very Strong Session? - Press Telegraph
06/22/16 07:07 AMThe Quest for an Effective Treatment for Pancreatic Cancer -
06/20/16 01:06 PMETF’s with exposure to Bellicum Pharmaceuticals, Inc. : June 20, 2016 -
06/17/16 03:06 PMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 02:56 PMSunTrust Robinson Humphrey Initiates Coverage on Bellicum Pharmaceuticals Inc to Buy - Trade Calls
06/09/16 11:45 AMNew Broker Ratings For Bellicum Pharmaceuticals, Inc. (BLCM) - FTSE News
06/08/16 11:23 AMBELLICUM PHARMACEUTICALS INC. (NASDAQ:BLCM) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:46 AMTalen Energy Corporation (NYSE:TLN) Soared 17.17%: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), AT&T, Inc ... - KC Register
06/03/16 02:57 PMBellicum Pharmaceuticals - Switch On To This - Seeking Alpha
06/02/16 08:56 PMStrong Sell Calls Count For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) At 0 - Investor Newswire - Strong Sell Calls Count For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) At 0Investor NewswireBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
06/02/16 11:38 AMBellicum Pharma (BLCM), LUMC Enter Natural High-Affinity TCRs Research Collaboration - StreetInsider.com - Bellicum Pharma (BLCM), LUMC Enter Natural High-Affinity TCRs Research CollaborationStreetInsider.comBellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) announced it has entered into a research agreement with Leiden University Medical Center (LUMC), Netherlands, to discover and validate natural high-affinity TCR (T cell receptor) product candidates ...Bellicum Pharma to Collaborate with Leiden University Medical Center to Discover Cancer-Targeting TCRs (NASDAQ ...Sonoran Weekly Reviewall 2 news articles »
06/02/16 06:15 AMBellicum Pharmaceuticals Enters into Research Collaboration with Leiden University Medical Center to Discover Natural High-Affinity TCRs - [at noodls] - New collaboration builds on current license and research agreement for TCR candidates, including BPX-701 HOUSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical ...
06/02/16 06:03 AMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an -
06/02/16 06:01 AM7:01 am Bellicum Pharma enters a research agreement with Leiden University Medical Center to discover and validate high-affinity TCR product candidates targeting several cancers -
06/01/16 06:13 AMBellicum to Present at the Jefferies 2016 Global Healthcare Conference - [at noodls] - HOUSTON--(BUSINESS WIRE)--Jun. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for ...
05/30/16 07:03 PMNext Weeks Broker Price Targets For Bellicum Pharmaceuticals, Inc. (BLCM) - Share Trading News - Next Weeks Broker Price Targets For Bellicum Pharmaceuticals, Inc. (BLCM)Share Trading NewsBellicum Pharmaceuticals, Inc. has a 50 day moving average of 10.25 and a 200 day moving average of 13.28. The stock's market capitalization is 303.30M, it has a 52-week low of 7.24 and a 52-week high of 29.33. The share price of the company (BLCM) ...and more »
05/24/16 01:54 PMETF’s with exposure to Bellicum Pharmaceuticals, Inc. : May 24, 2016 -
05/23/16 12:13 PMBellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/19/16 06:22 AMBellicum Announces Data Presentations at the Annual Meetings of the American Society of Clinical Oncology and the European Hematology Association - [at noodls] - HOUSTON--(BUSINESS WIRE)--May 19, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for ...
02/26/16 01:14 PMBellicum Pharmaceuticals Inc 15.7% Potential Upside Now Implied by Citigroup - DirectorsTalk Interviews - Bellicum Pharmaceuticals Inc 15.7% Potential Upside Now Implied by CitigroupDirectorsTalk InterviewsBellicum Pharmaceuticals Inc using SYMBOL/TICKER code NASDAQ:BLCM had its stock rating noted as 'Initiated' with the recommendation being set at 'NEUTRAL' yesterday by research analysts at Citigroup. Bellicum Pharmaceuticals Inc are listed in the ...and more »
02/25/16 05:52 AMCoverage initiated on Bellicum Pharmaceuticals by Citigroup -
02/22/16 12:43 PMBellicum Pharmaceuticals Gains 8%, Company Receives Orphan Drug Designation For Its BPX-501 Therapy - Shares of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) were trading higher by 8 percent on Monday after the company announced that the U.S. Food and Drug Administration (FDA) granted its BPX-501 with an orphan drug designation. The FDA designation is for the combination of BPX-501 genetically modified T cells and activator agent rimiducid as "replacement T-cell therapy for the treatment of immunodeficiency and ...Full story available on Benzinga.com
02/22/16 06:00 AMFDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant - [Business Wire] - Bellicum Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S.
02/07/16 01:51 PMBellicum Pharmaceuticals Incorporated (NASDAQ:BLCM) Short Interest Increased By 5.18% - fdanewsalert.com - Bellicum Pharmaceuticals Incorporated (NASDAQ:BLCM) Short Interest Increased By 5.18%fdanewsalert.comThe short interest to Bellicum Pharmaceuticals Incorporated's float is 10.41%. The stock decreased 6.00% or $0.67 during the last trading session, hitting $10.5. About 254,070 shares traded hands. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has ...and more »
01/29/16 01:43 PMAnalyst Price Target on Bellicum Pharmaceuticals, Inc. - Market Briefing - Analyst Price Target on Bellicum Pharmaceuticals, Inc.Market BriefingBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $40 in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM). However, the stock price could fluctuate by $ 7.07 from ...and more »
01/28/16 01:38 PMRecent Broker Updates On Bellicum Pharmaceuticals, Inc. (BLCM) - Risers & Fallers - Recent Broker Updates On Bellicum Pharmaceuticals, Inc. (BLCM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Bellicum Pharmaceuticals, Inc. (BLCM). The latest broker reports which are currently outstanding on Wednesday 27th January state 2 analysts have a rating of “strong buy”, ...
01/26/16 01:37 PMBellicum Pharmaceuticals, Inc. Analyst Rating Update - WallStreet Prudent - Bellicum Pharmaceuticals, Inc. Analyst Rating UpdateWallStreet PrudentBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has received a short term rating of hold from research analysts at Zacks Investment Research with a rank of 3. The company has been rated an average of 1 by 2 Wall Street Analysts. 2 analysts have added the ...and more »
01/15/16 03:39 PMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
01/11/16 12:10 PMThis Week Is Paramount For Biotech Stocks -
01/11/16 07:47 AMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Other Events -
01/11/16 07:18 AMBellicum Pharmaceuticals Announces Submission of BPX-701 and BPX-601 Clinical Trial Protocols for Review by the NIH RAC - [at noodls] - --(BUSINESS WIRE)--Jan. 11, 2016-- (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood ...
01/05/16 11:30 AMCommit To Buy Bellicum Pharmaceuticals At $12.50, Earn 23.2% Annualized Using Options - Investors eyeing a purchase of Bellicum Pharmaceuticals Inc (BLCM) stock, but cautious about paying the going market price of $19.50/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put ...
01/05/16 07:11 AMBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 -
01/05/16 06:21 AMMy Top Biotech Stock for 2016 -
12/24/15 12:06 PMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Unregistered Sale of Equity Securities -
12/15/15 04:15 PMBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers -
12/15/15 08:05 AMBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 15, 2015 -
About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy, and dendritic cell vaccines. The Company's product candidates include BPX-501, BPX-201, BPX-401, BPX-601 and BPX-701. It is also engaged in other development programs, such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLCM
  • CUSIP:
Key Metrics:
  • Previous Close: $12.42
  • 50 Day Moving Average: $11.28
  • 200 Day Moving Average: $12.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $335.14M
  • Current Quarter EPS Consensus Estimate: $-2.22 EPS
Additional Links:
Bellicum Pharmaceuticals (NASDAQ:BLCM) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha